Department of Plastic and Reconstructive Surgery, Medical University Graz, Graz, Austria.
Clin Cosmet Investig Dermatol. 2013 Sep 24;6:211-9. doi: 10.2147/CCID.S41537. eCollection 2013.
Three botulinum neurotoxin type A preparations (incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA) are widely approved in Europe and in the US for the treatment of glabellar frown lines. The purpose of this study was to determine and compare the time to onset and duration of treatment effect of incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA for the treatment of glabellar frown lines.
Subjects aged 20-60 years with moderate to severe glabellar frown lines received one treatment of either 21 units (U) incobotulinumtoxinA, 21 U onabotulinumtoxinA, or 63 U abobotulinumtoxinA. Assessments were made over a period of 180 days. Onset of treatment effect was defined as the day that the observer noted a decrease in glabellar muscle activity compared with baseline photographs and videos. Duration of treatment effect was defined as the time until glabellar muscle action returned to the baseline level. Analyses were performed using a Weibull log(T) regression model.
The study enrolled 180 subjects; 60 per group. For all three products, onset of treatment effect occurred earlier in female subjects compared to male subjects. For both sexes, a significantly earlier time to onset of treatment effect was seen for incobotulinumtoxinA compared to onabotulinumtoxinA and abobotulinumtoxinA; in female subjects these times were 3.02 days, 5.29 days, and 5.32 days, respectively. The duration of treatment effect was longer for incobotulinumtoxinA compared to onabotulinumtoxinA and abobotulinumtoxinA; for all products, treatment effect duration was longer in females than in males. Time to onset was not a predictor of treatment duration.
IncobotulinumtoxinA demonstrated a more rapid onset and a longer duration of treatment effect than onabotulinumtoxinA (1:1 dose ratio) and abobotulinumtoxinA (1:3 dose ratio). Onset of effect was faster and duration of effect was longer in female subjects compared to male subjects.
三种肉毒神经毒素 A 制剂（ 利奥西呱毒素 A 、 保妥适肉毒毒素 A 和 丽舒妥肉毒毒素 A ）在欧洲和美国被广泛批准用于治疗眉间竖纹。本研究的目的是确定和比较利奥西呱毒素 A 、保妥适肉毒毒素 A 和丽舒妥肉毒毒素 A 治疗眉间竖纹的起效时间和治疗效果持续时间。
年龄在 20-60 岁之间、有中度至重度眉间竖纹的受试者分别接受 21 单位（U ）利奥西呱毒素 A 、21 U 保妥适肉毒毒素 A 或 63 U 丽舒妥肉毒毒素 A 治疗。在 180 天的时间内进行评估。治疗效果的起始定义为观察者观察到与基线照片和视频相比，眉间肌肉活动减少的那一天。治疗效果持续时间定义为眉间肌肉活动恢复到基线水平的时间。使用威布尔对数（T ）回归模型进行分析。
该研究纳入了 180 名受试者，每组 60 名。对于所有三种产品，女性受试者的治疗效果起始时间均早于男性受试者。对于所有性别，利奥西呱毒素 A 的起效时间明显早于保妥适肉毒毒素 A 和丽舒妥肉毒毒素 A ；对于女性，这些时间分别为 3.02 天、5.29 天和 5.32 天。利奥西呱毒素 A 的治疗效果持续时间长于保妥适肉毒毒素 A 和丽舒妥肉毒毒素 A ；对于所有产品，女性的治疗效果持续时间均长于男性。起效时间不是治疗持续时间的预测因素。
利奥西呱毒素 A 与保妥适肉毒毒素 A （1:1 剂量比）和丽舒妥肉毒毒素 A （1:3 剂量比）相比，起效更快，治疗效果持续时间更长。与男性相比，女性的起效更快，效果持续时间更长。
